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heparin (UFH) in many patients to achieve greater clini-
cal efﬁcacy and pharmacoeconomic efﬁciency. Most hos-
pitals have not achieved clinically effective use of LMWH
and UFH in the treatment and prevention of thrombotic
disorders. The Clinical Effectiveness Initiative (CEI) was
designed to help hospitals achieve better data assessment
to measure patient outcomes, reduce medical errors,
reduce risk, and reach towards optimal ﬁnancial perfor-
mance in these patient groups. METHODS: CEI begins
with analysis of data available from the UB-92 and phar-
macy or cost-accounting systems. The actuarial analysis
provides a risk-adjusted comparison of patient cohorts
receiving antithrombotics (LMWH or UFH). Results are
reported to the institution in a format suitable for use
with performance improvement activities and physicians.
The total cost for each cohort is broken down into drug
acquisition costs and costs associated with laboratory
tests, level of care, supplies and length of stay. RESULTS:
Results completed from two hospitals in 87 DRGs that
had at least 10 discharges in each drug category (5374
LMWH, 9380 UFH) showed a case mix adjusted average
savings of $698 per discharge. The study to-date has
showed that the use of LMWH reduced overall cost in
many high-use categories, despite the higher drug acqui-
sition cost. Those included DVT, Hip and Knee replace-
ment cases. Findings also demonstrated an opportunity
for substantial savings with greater selective use of
LMWH in several cohorts that will shared in chart form.
The data analysis and structured interviews with hospital
leadership presented valuable insights into how best to
facilitate changes in practice patterns that can be contin-
ually measured. CONCLUSIONS: We conclude that the
data assessment and efﬁciency modeling capabilities of
CEI are powerful tools to help hospitals achieve clinical
effectiveness, especially when integrated into a hospital’s
performance improvement program.
PHARMACOECONOMIC & OUTCOMES
RESEARCH METHODOLOGY STUDIES—
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JEED PROJECT
Fukuda T,Tsutani K, Kobayashi Y
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OBJECTIVES: The Japan Economic Evaluation Database
(JEED) project aims for critical appraisal of health eco-
nomic evaluation studies in Japan and build a database
with structured abstracts in collaboration with NHS-
EED. With careful preparation in 2001, we performed
handsearching of all the scientiﬁc articles and reports in
the health economic ﬁelds in Japan in 2002. We analyzed
current status of economic evaluation studies and
methodological issues. METHODS: Since January 2002,
we started to hand-search all articles and reports pub-
lished in Japanese journals. Key words for handsearching
were types of economic evaluations such as cost-
effectiveness analysis or cost-utility analysis and method-
ological terms such as utility score, willingness to pay,
QOL measurement and costing. We also adopted words
for study areas such as health economic evaluations and
pharmacoeconomics. We classiﬁed the articles into some
categories and picked up methodological issues in Japan.
RESULTS: Up to the end of September 2002, we identi-
ﬁed 223 articles and reports related to health economic
evaluations that appeared in a total of 4881 journals.
Most of the articles were general remarks or proceedings.
Thirty-four articles out of 233 were classiﬁed as original
articles, only 6 of which could be identiﬁed as full eco-
nomic evaluations. Nineteen articles were on costing and
4 were on measuring effectiveness or utility. We picked
up some issues in economic evaluation studies in Japan.
Most of the studies used reimbursement fee though there
were some studies for actual costing. Because QOL data
for health status were limited in Japanese population,
many studies adopted data from foreign countries. There
were some articles which did not use terms for economic
evaluation studies correctly. CONCLUSIONS: To
promote good economic evaluation studies in Japan, sys-
tematic critical appraisals and dissemination of informa-
tion of good studies are needed. We may have to consider
methodological guidelines or recommendations for good
economic evaluation studies.
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OBJECTIVES: Guidelines for conducting cost-utility
analyses (CUAs) contain inconsistent recommendations
for selecting cost, quality of life, and discount rate para-
meters. Sensitivity analyses can indicate whether adher-
ing to different guidelines results in different policy
recommendations. The purpose of this study is to inves-
tigate the use of sensitivity analyses to test economic 
parameters in the cost-utility literature. METHODS: Rec-
ommendations from published guidelines are summa-
rized. CUAs of pharmaceutical therapies identiﬁed in a
prior study (N = 71 articles) were reviewed and further
audited. We identiﬁed threshold CU ratios (N = 36) and
base cases for which sensitivity analyses were reported (N
= 123). For each base case, up to 2 sensitivity analyses
for cost (N = 97), quality of life (N = 136), and discount
rate (N = 127) were examined. RESULTS: There are sub-
stantial disagreements among the guidelines regarding
economic parameters. The most frequently mentioned
threshold CU ratios were $20,000/QALY, $50,000/
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QALY, and $100,000/QALY. The proportions of sensi-
tivity analyses reporting quantitative results that crossed
the threshold above the base case CU ratio were 23% for
cost sensitivity analyses, 38% for quality-of-life sensitiv-
ity analyses, and 15% for discount rate sensitivity analy-
ses. There was no difference in quality ratings between
CUAs that reported sensitivity analysis results that
exceeded the thresholds (N = 17) and those that did not,
but the overall quality and completeness ratings were only
moderate. CONCLUSIONS: Sensitivity analyses for eco-
nomic parameters are widely reported and can be used to
identify whether choosing different assumptions leads to
a different decision. Different decisions occur more fre-
quently for cost and quality-of-life assumptions than for
discount rate assumptions. Sensitivity analyses for cost
and quality-of-life parameters should be used to test alter-
native guideline recommendations, but sensitivity analy-
ses for discount rates do not have the same import.
Adhering to recommendations on performing cost-
effectiveness analyses would improve the overall quality
of these types of studies.
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FACILITATING USER INTERACTION WITH
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Caro J, Magno J,Ward AJ
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Although a pharmacoeconomic model is usually created
for one setting, there is often interest in using it in other
jurisdictions. This requires that it be modiﬁable by other
users, and given the complexity of most models, this 
may be difﬁcult to do. OBJECTIVE: To develop a low
cost tool that standardizes model inputs and outputs 
and allows models to be easily edited and analyzed.
METHODS: An electronic viewer (MODEL-IT®) was
developed as a “container” that allows display and inter-
action with disease models. The tool is programmed to
work as a stand-alone application in a Windows© envi-
ronment. It is designed to read any model that has been
formatted according to a simple set of rules. The model
engine itself can be in any format, including EXCEL. The
screens were developed to maintain a consistent format
yet be able to display inputs and outcomes pertinent to
the speciﬁc model. Tool functions are accessed by self-
explanatory buttons. RESULTS: MODEL-IT® classiﬁes
inputs into speciﬁc categories including population 
characteristics, disease parameters, model controls (e.g.
number of replications), treatment details and costs. All
ﬁelds are editable. Outcomes are model-speciﬁc but are
also classiﬁed into costs, effectiveness, survival and cost-
effectiveness. Model versions can be saved for later use,
and all screens can be printed or exported to other pro-
grams. Model documentation can be incorporated as 
a help ﬁle. The Model-IT® viewer is available free of
charge. CONCLUSIONS: A viewer has been developed
to allow users to interact with models in a standard
format and to increase interdisciplinary access and under-
standing of models in order to support their wider use in
decision-making about new pharmaceuticals.
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OBJECTIVES: Our objectives were to investigate: 1)
whether methods and reporting of published cost-utility
analyses (CUAs) have improved over time; and 2)
whether quality is higher in journals that published more
CUAs. METHODS: A systematic search of the English-
language medical literature identiﬁed 522 original CUAs
published from 1976 through 2001. Each study was inde-
pendently audited by two trained readers for a core set
of data elements on study methodology and reporting,
and a subjective assessment of overall study quality on 
a scale from 1 (low) to 7 (high)—data available at:
http://www.hsph.harvard.edu/cearegistry/. High-volume
journals were deﬁned as those publishing 4 or more CUAs
from 1976–2001. This study updates our previous analy-
sis, which examined the quality of CUAs from 1976 to
1997. RESULTS: Several key elements improved over
time. Comparing the 1998–2001 period (n = 294) to
1976–1997 (n = 228), articles improved in: clearly pre-
senting the study perspective (73% vs. 52%, p < 0.001);
performing sensitivity analyses (93% vs. 89%, p = 0.092);
discounting both costs and QALYs (82% vs. 72%, p =
0.016); and calculating and reporting incremental ratios
(69% vs. 46%, p < 0.001). More studies in the latter
period took the societal perspective (30% vs. 23%). The
overall quality score improved as well, though the change
was not signiﬁcant (4.25 vs. 4.10, p = 0.19). The pro-
portion of studies disclosing funding sources did not
change (64% vs. 65%, p = 0.88). Average quality score
is greater in higher- vs. lower-volume journals (4.5 vs. 3.7,
p < 0.001). CONCLUSION: Published CUAs have
improved over time, though many still omit basic ele-
ments. Clinical journals, particularly those with little
experience publishing CUAs, need to adopt and enforce
standard protocols for conducting and reporting.
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FROM CLINIC TRIAL DATA
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OBJECTIVES: Economic evaluation is increasing
common in clinical trials. Often, individuals’ health care
costs are not observed in these trials, rather health care
cost estimates are often calculated from observed resource
